NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease<
28 Sep 2026

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026
Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer<
24 Sep 2026

Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

More than half of the patients planned for the clinical study have already been enrolled,

Anaconda Biomed Secures $56 Million Financing from New and Existing Investors<
23 Sep 2026

Anaconda Biomed Secures $56 Million Financing from New and Existing Investors

Clinical Evidence Shows High Reperfusion and First Pass Success Rates with the Device
Ysios Capital 2025 / H1 2026 Review<
28 Jul 2026

Ysios Capital 2025 / H1 2026 Review

Over the past eighteen months, we have combined strong portfolio execution with the expansion of our investment platform.
Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch<
28 Jul 2026

Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial execution
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease<
24 Jul 2026

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline<
22 Jul 2026

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors<
08 Jul 2026

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis<
07 Jul 2026

Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis

Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis<
02 Jul 2026

Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis

> 50% of target enrollment reached across 20 sites in the United States

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.